Immune-related lichenoid mucocutaneous erosions during anti-PD-1 immunotherapy in metastatic renal cell carcinoma - A case report

Nivolumab belongs to the standard treatment options in metastatic renal cell carcinoma. Despite promising responses, a new spectrum of “immune-related” adverse effects has to be managed in daily clinical practice. A 74-year-old patient was treated with nivolumab in fourth-line. After 18 cycles, trea...

Descripción completa

Detalles Bibliográficos
Autores principales: Lindner, Andrea Katharina, Schachtner, Gert, Tulchiner, Gennadi, Staudacher, Nina, Steinkohl, Fabian, Nguyen, Van Anh, Horninger, Wolfgang, Pichler, Renate
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6251064/
https://www.ncbi.nlm.nih.gov/pubmed/30505683
http://dx.doi.org/10.1016/j.eucr.2018.11.008
Descripción
Sumario:Nivolumab belongs to the standard treatment options in metastatic renal cell carcinoma. Despite promising responses, a new spectrum of “immune-related” adverse effects has to be managed in daily clinical practice. A 74-year-old patient was treated with nivolumab in fourth-line. After 18 cycles, treatment was stopped due to severe adverse mucocutaneous reactions confirming a lichen ruber pemphigoides. CT scans during treatment discontinuation show stable disease since more than 14 months. Immunotherapy can cause mucocutaneous immune-mediated adverse reactions. The time of onset to cutaneous adverse effects is variable. Early recognition and treatment are essential in mitigating the severity of those adverse events.

Ejemplares similares